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PCLINICAL RESEARCH Acute Coronary Syndrome
Stem Cell Mobilization by Granulocyte
Colony-Stimulating Factor for Myocardial
Recovery After Acute Myocardial Infarction
A Meta-Analysis
Dietlind Zohlnhöfer, MD,* Alban Dibra, MD,* Tobias Koppara, MD,* Antoinette de Waha, MD,*
Rasmus Sejersten Ripa, MD,† Jens Kastrup, MD,† Marco Valgimigli, MD, PHD,‡
Albert Schömig, MD,* Adnan Kastrati, MD*
Munich, Germany; Copenhagen, Denmark; and Ferrara, Italy
Objectives The objective of this meta-analysis was to evaluate the effect of stem cell mobilization by granulocyte colony-
stimulating factor (G-CSF) on myocardial regeneration on the basis of a synthesis of the data generated by ran-
domized, controlled clinical trials of G-CSF after acute myocardial infarction (AMI).
Background Experimental studies and early-phase clinical trials suggest that stem cell mobilization by G-CSF may have a pos-
itive impact on cardiac regeneration after AMI. The role of G-CSF in patients with AMI remains unclear consider-
ing the inconsistent results of several clinical trials.
Methods For our analysis, PubMed, the Cochrane Central Register of Controlled Trials, conference proceedings from major
cardiology meetings, and Internet-based sources of information on clinical trials in cardiology from January 2003
to August 2007 served as sources. Two reviewers independently identified studies and abstracted data on sam-
ple size, baseline characteristics, and outcomes of interest. Eligible studies were randomized trials with stem
cell mobilization by G-CSF after reperfused AMI that reported data regarding the change in left ventricular ejec-
tion fraction (LVEF) at follow-up.
Results Ten trials using stem cell mobilization by G-CSF, including 445 patients, met the inclusion criteria. Significant
improvement in LVEF at follow-up was observed in both the G-CSF and placebo groups. Compared with placebo,
stem cell mobilization by G-CSF did not enhance the improvement of LVEF at follow-up (mean difference 1.32%
[95% confidence interval 1.52 to 4.16; p  0.36]). Moreover, the mean difference of reduction of infarct size
between the treatment and placebo groups was 0.15 (95% confidence interval 0.38 to 0.07, p  0.17).
Conclusions Cumulatively, available evidence does not support a beneficial effect of G-CSF in patients with AMI after
reperfusion. (J Am Coll Cardiol 2008;51:1429–37) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.11.073w
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beart failure develops in a relevant number of patients with
cute myocardial infarction (AMI) caused by irreversible
yocardial damage and ventricular remodeling despite early
eperfusion strategies (1,2). Cell-based therapeutic strate-
ies seem to be a promising tool to beneficially influence
entricular remodeling after AMI. Although the underlying
echanism remains controversial, numerous animal studies
ave documented that cytokine-induced mobilization of
one marrow–derived stem cells after AMI is associated
rom the *Deutsches Herzzentrum, Technische Universität München, Munich,
ermany; †Department of Cardiology, The Heart Centre, University Hospital
igshospitalet, Copenhagen, Denmark; and the ‡Cardiovascular Institute, University
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2, 2007, accepted November 26, 2007.ith a reduction in infarct size, improvement in left ven-
ricular ejection fraction (LVEF), and survival (3–6). More-
ver, a meta-analysis recently showed a moderate benefit
rom intracoronary stem cell transplantation in patients with
MI after successful reperfusion (7).
See page 1438
Granulocyte colony-stimulating factor (G-CSF) is an
ffective stimulus for mobilization of bone marrow-derived
tem cells into the peripheral blood. A number of recent
tudies, mostly involving limited numbers of patients, have
valuated the use of G-CSF as a less invasive stem cell-
ased strategy for myocardial regeneration in patients with
MI after successful reperfusion (8–17). However, these
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Meta-Analysis of G-CSF in AMI April 15, 2008:1429–37trials have obtained mixed results
with respect to improvement of
left ventricular (LV) function af-
ter G-CSF–induced stem cell
mobilization. Moreover, in an
early safety and feasibility study
of stem cell mobilization in pa-
tients with AMI, G-CSF ther-
apy was associated with an in-
creased risk of restenosis (18).
Therefore, we herein summarize
available experience in this field
in the form of a meta-analysis of
the effect of stem cell mobiliza-
tion by G-CSF on changes in
LVEF and infarct size in patients
with AMI.
Methods
bjective. The objective of our meta-analysis was to assess
he efficacy and safety of G-CSF–induced stem cell mobi-
ization for myocardial recovery in patients with AMI.
riteria for study selection. For this meta-analysis, stud-
es were selected that included patients with AMI who
ere assigned to stem cell mobilization by G-CSF in
andomized, controlled trials. All studies had to report
he outcomes of interest during a follow-up period of at
east 1 month after the index procedure. No restriction
riteria were imposed with regard to the form of study
ublication.
utcomes and definitions. The primary outcome of in-
erest was change in LVEF. The secondary end point was
hange in infarct size. The angiographic outcome of interest
as binary restenosis, which was defined as diameter steno-
is of at least 50% at follow-up, measured by quantitative
ngiography in the area, including the stented area as well as
he 5-mm margins proximal and distal to the stent.
We also analyzed clinical end points such as target vessel
evascularization, myocardial infarction (MI), death, and
he composite of death or MI.
ata sources. We searched PubMed and the Cochrane
entral Register of Controlled Trials for trials comparing
tem cell mobilization with G-CSF versus placebo treat-
ent in patients with AMI. In addition, we searched
onference proceedings from the American College of
ardiology, American Heart Association, and European
ociety of Cardiology. Searches were restricted to the period
rom January 2003 to August 2007. We reviewed the
eer-reviewed publications identified through searches us-
ng the following key words: “granulocyte colony stimulat-
ng factor,” “G-CSF,” “cytokine,” “stem cells,” “coronary
rtery disease,” “acute myocardial infarction,” “primary per-
utaneous coronary intervention” (PCI), and “primary PCI.”
elevant reviews and editorials from major medical journals
Abbreviations
and Acronyms
AMI  acute myocardial
infarction
CD34  cluster of
differentiation 34
CI  confidence interval
G-CSF  granulocyte
colony-stimulating factor
LV  left
ventricle/ventricular
LVEF  left ventricular
ejection fraction
MI  myocardial infarction
PCI  percutaneous
coronary intervention
WMD  weighted mean
differencesublished within the last year were identified and assessed bor possible information on trials of interest. Internet-based
ources of information on the results of clinical trials in
ardiology were also searched.
ata collection and assessment of quality. Studies were
elected and data were extracted independently by 2 review-
rs (D.Z., A.D.). Disagreements were resolved by consen-
us. We recorded the following characteristics, in addition
o the number of participating patients: LV function at
aseline and follow-up, infarct size at baseline and follow-
p, angiographic restenosis, target vessel revascularization,
I, death, and the composite of death and MI. Raw data
btained from source information of the individual studies
ere used for all analyses.
tatistical analysis. Weighted mean differences (WMDs)
ith 95% confidence intervals (CIs) were computed as
ummary statistics. A random-effects model using the
ethod of DerSimonian and Laird was used to calculate
ooled WMD (19). Heterogeneity was explored using the
hi-square test. The quantity of heterogeneity across trials
as measured by the I2 statistic as proposed by Higgins et
l. (20). We assessed publication bias with respect to the
rimary outcome of interest, increase in LVEF, using the
egg adjusted rank correlation test according to the method
f Begg and Mazumdar (21) and regression asymmetry test
y Egger et al. (22). A sensitivity analysis was performed by
ssessing the contribution of individual studies to the
ummary effect estimate with respect to the primary out-
ome. This was done by excluding each trial 1 at a time and
omputing meta-analysis estimates for the remaining stud-
es. The effect of study variables was assessed using meta-
egression. Results were considered statistically significant at
 0.05. Statistical analyses were performed with Stata
oftware, version 9.2 (Stata Corp., College Station, Texas).
esults
andomized trials investigating the effect of G-CSF after
MI. Our search identified 10 randomized trials that
nvestigated the effect of G-CSF–induced stem cell mobi-
ization in 445 patients with AMI after successful reperfu-
ion (8–17) (Table 1).
The G-CSF treatment resulted in a dose-dependent
obilization of cluster of differentiation 34 positive
CD34) stem cells from the bone marrow to the peripheral
lood (Table 2). The lowest CD34 cell count was seen in
he study with the lowest G-CSF dose and the shortest
uration of G-CSF treatment (14), whereas it was highest
n the study with the highest dose and longest duration of
reatment (17) (Table 2).
Among the 10 included trials, 4 were double-blinded
REVIVAL-2 [Regenerate Vital Myocardium by Vigorous
ctivation of Bone Marrow Stem Cells] [10], STEMMI
Stem Cells in Myocardial Infarction] [11], G-CSF-
TEMI [Granulocyte Colony-Stimulating Factor ST-
egment Elevation Myocardial Infarction] [12], and the trial
y Ellis et al. [13]). The remaining 6 trials did not have a
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April 15, 2008:1429–37 Meta-Analysis of G-CSF in AMIouble-blinded design: FIRSTLINE-AMI (Front-Integrated
evascularization and Stem Cell Liberation in Evolving
cute Myocardial Infarction) (9), the Rigenera study (15),
AGIC Cell 1 (Myocardial Regeneration and Angiogen-
sis in Myocardial Infarction with G-CSF and Intra-
oronary Stem Cell Infusion 1) (16), as well as the trials by
algimigli et al. (8), Takano et al. (14), and Suarez de Lezo
t al. (17) all had a randomized control group (Table 1).
Concerning the primary end points, G-CSF studies
aried considerably (Table 1). Change in ejection fraction
as the primary end point in 6 trials: the G-CSF-STEMI
rial, the MAGIC Cell 1 trial, the Rigenera trial, and the
rials by Ellis et al., Takano et al., and Suarez de Lezo et al.
12–17). Two trials did not specify a primary end point
ecause they were mainly designed as safety and feasibility
tudies (8,9). One trial investigated reduction in infarct size
s a primary end point and a change in LVEF as a secondary
ain Characteristics of the Trials
Table 1 Main Characteristics of the Trials
Trial
Double
Blinding
Number of
Patients Therapy
Reperf
Treatm
Valgimigli et al. (8) No 20 G-CSF PCI
FIRSTLINE-AMI (9) No 50 G-CSF PCI
REVIVAL-2 (10) Yes 114 G-CSF PCI
STEMMI (11) Yes 78 G-CSF PCI
G-CSF-STEMI (12) Yes 44 G-CSF PCI
Ellis et al. (13) Yes 18 G-CSF PCI
Takano et al. (14) No 40 G-CSF PCI
Rigenera (15) No 41 G-CSF PCI
MAGIC Cell 1 (16) No 20 G-CSF PCI
Suarez de Lezo et al. (17) No 20 G-CSF PCI
Seven patients per group had PCI.
FIRSTLINE-AMI  Front-Integrated Revascularization and Stem Cell Liberation in Evolving Acut
-CSF-STEMI Granulocyte Colony-Stimulating Factor ST-Segment Elevation Myocardial Infarction
ntra-Coronary Stem Cell Infusion 1 trial; MRI  magnetic resonance imaging; PCI  percutaneo
arrow Stem Cells trial; SPECT  single-photon emission computed tomography; STEMMI  Stem
G-CSF Therapy
Table 2 G-CSF Therapy
Trial
G-CSF Dosage
(g/kg/day)
Valgimigli et al. (8) 5
FIRSTLINE-AMI (9) 10
REVIVAL-2 (10) 10
STEMMI (11) 10
G-CSF-STEMI (12) 10
Ellis et al. (13) (5 g G-CSF) 5
Ellis et al. (13) (10 g G-CSF) 10
Takano et al. (14) 2.5
Rigenera (15) 10
MAGIC Cell 1 (16) 10
Suarez de Lezo et al. (17) 10CD34  cluster of differentiation 34; other abbreviations as in Table 1.nd point (10). The STEMMI trial measured the change in
ystolic wall thickening as the primary end point (11).
Moreover, trials used varying imaging modalities to
easure LVEF (Table 1). The LVEF was measured by
agnetic resonance imaging in 3 trials (10–12), by echo-
ardiography in 3 trials (9,13,15), by single-photon emission
omputed tomography in 3 trials (8,14,16), and by left
entriculography in the trial by Suarez de Lezo et al. (17).
Reperfusion treatment and time of reperfusion differed
etween the trials (Table 1). In most trials except for the
rial by Valgimigli et al. (8) and the Rigenera trial (15),
atients had successful mechanical reperfusion after AMI.
n the study by Valgimigli et al. (8), only 14 (i.e., those
resenting during the acute phase of MI) of 20 patients
nderwent primary PCI. Likewise, in the Rigenera trial
9% of patients in the G-CSF compared with 44% in the
ontrol group were treated by primary PCI (15).
Primary End Point Method
Duration of
Follow-Up
(Months)
Safety and feasibility SPECT 6
Safety and left ventricular function ECHO 4
Change in infarct size MRI 4
Change in systolic wall thickening MRI 6
Change in ejection fraction and
systolic wall thickening
MRI 3
Safety and change in ejection fraction ECHO 1
Changes in left ventricular function
and volume
SPECT 6
Change in ejection fraction and left
ventricular volume
ECHO 5
Change in ejection fraction SPECT 24
Change in ejection fraction Ventriculography 3
rdial Infarction trial; G-CSF  granulocyte colony-stimulating factor; ECHO  echocardiography;
AGIC Cell 1Myocardial Regeneration and Angiogenesis in Myocardial Infarction with G-CSF and
nary intervention; REVIVAL-2  22 Regenerate Vital Myocardium by Vigorous Activation of Bone
in Myocardial Infarction trial.
Duration of G-CSF
dministration (day)
Number of Cells/l
(CD34)
G-CSF Control
4 28 8 7 2
5 65 37 4 2
5 72 154 5 6
6 55 53 4 2
5 46 33 2 1
5 37 30 7 7
5 29 14 7 7
5 15 19 2 1
5 50 35 2 2
4 — —
10 88 79 —usion
ent
*
e Myoca
trial; MA
t
g
l
w
g
s
t
W
s
(
1
b
i
m
(
w
w
t
n
E
w
b
n
c
t
d
t
b
C
h
s
o
p
s
o
d
(
s
p
m
f
r
e
t
f
w
T
(
s
e
c
an
ge
in
EF
Fr
om
B
as
el
in
e
to
Fo
llo
w
-U
p
ab
le
3
C
ha
ng
e
in
EF
Fr
om
B
as
el
in
e
to
Fo
llo
w
-U
p
EF
B
as
el
in
e
EF
Fo
llo
w
-U
p

EF
Ti
m
e
(h
)
Fr
om
A
M
I
to
P
C
I
Ti
m
e
(h
)
Fr
om
P
C
I
to
G
-C
S
F
Ti
m
e
(h
)
Fr
om
A
M
I
to
G
-C
S
F
G
-C
S
F
C
on
tr
ol
G
-C
S
F
C
on
tr
ol
G
-C
S
F
C
on
tr
ol
G
-C
S
F
C
on
tr
ol
G
-C
S
F
C
on
tr
ol
G
-C
S
F
C
on
tr
ol
al
gi
m
ig
li
et
al
.(
8
)
4
1

1
0
4
2

7
5
0

1
5
4
8

9
9

5
6

3

1
2

1
2
3
7

6
6
—
—
—
IR
S
TL
IN
E-
A
M
I(
9
)
4
8

4
4
7

5
5
4

8
4
3

5
6

9

4

7
5

2
5

2
1

1
—
—
—
EV
IV
A
L-
2
(1
0
)
5
1

8
4
9

9
5
2

8
5
1

9
1

4
2

5

1
2

1
2
1
1
4

3
1
1
1
4

2
7
—
—
TE
M
M
I(
1
1
)
5
1

1
5
5
5

1
1
6
0

1
2
6
2

1
2
9

1
1
8

1
0
4
4
3
0
2
8
—
—
-C
S
F-
S
TE
M
I(
1
2
)
4
1

1
2
4
4

9
4
7

1
2
5
0

1
2
6

9
5

1
0
3
2

4
5
5
1

5
3
3
1

2
4
3
9

2
8
—
—
lli
s
et
al
.(
1
3
)
(5

g
G
-C
S
F)
3
7

8
3
3

2
4
1

1
0
4
2

8
5

1
1
8

1
0
6

4
1
5

1
8
—
—
3
8

8
4
2

1
1
lli
s
et
al
.(
1
3
)
(1
0

g
G
-C
S
F)
3
4

5
3
4

2
3
9

7
4
2

8
5

7
8

1
0
1
2

1
7
1
5

1
8
—
—
4
1

6
4
2

1
1
ak
an
o
et
al
.(
1
4
)
4
7

1
1
4
6

1
0
5
2

1
1
4
9

1
4
5
3
7

6
5

3

2
4

2
4

2
1

2
1
ig
en
er
a
(1
5
)
4
0

6
3
8

6
4
5

6
3
8

8
5

9
0

6
—
—

1
2
0
—
—
—
A
G
IC
-C
EL
L
1
(1
6
)
5
3

1
4
4
4

9
5
3

1
3
5
1

9
0
8

7
—
—
—
—
—
—
ua
re
z
de
Le
zo
et
al
.(
1
7
)
3
7

5
3
9

6
4
2

1
4
4
5

8
4

1
3
6

1
0
—
—
—
—

1
2
0
—

ac
ut
e
m
yo
ca
rd
ia
li
nf
ar
ct
io
n;
EF

ej
ec
tio
n
fr
ac
tio
n;
ot
he
r
ab
br
ev
ia
tio
ns
as
in
Ta
bl
e
1
.
1432 Zohlnhöfer et al. JACC Vol. 51, No. 15, 2008
Meta-Analysis of G-CSF in AMI April 15, 2008:1429–37Time from onset of symptoms to PCI also varied among
he studies (Table 3). In the G-CSF-STEMI trial investi-
ating the effect of G-CSF after subacute MI undergoing
ate revascularization, the time from symptom onset to PCI
as 32  45 h in the G-CSF and 51  53 h in the control
roup (12). In the FIRSTLINE-AMI trial, time from
ymptom onset to PCI was within 5 h in both groups (9).
Likewise, the mean time from PCI to G-CSF adminis-
ration differed considerably among the trials (Table 3).
hereas in the FIRSTLINE-AMI trial, G-CSF treatment
tarted very early within 89  35 min after successful PCI
9), in the REVIVAL-2 trial (10) and in the MAGIC Cell
trial (16), G-CSF was given as late as 5 days after PCI.
Patients were frequently treated with aspirin, clopidogrel,
eta-blockers, statins, and angiotensin-converting enzyme
nhibitors as standard optimal medical heart failure treat-
ent. Only in the trials by Ellis et al. (13) and Takano et al.
14) were patients not frequently treated with beta-blockers,
hereas in the STEMMI trial only 40% to 50% of patients
ere treated with angiotensin-converting enzyme inhibi-
ors. Diuretics, including an aldosterone antagonist, were
ot given frequently.
ffect of G-CSF treatment on LV recovery. Compared
ith control conventional treatment, stem cell mobilization
y G-CSF had a beneficial effect on neither LV function
or infarct size. As expected, in both groups LVEF in-
reased during the follow-up period (Table 3). In only 1
rial, the FIRSTLINE-AMI, LV function significantly
eteriorated in the control group, whereas it improved in
he treatment group (9).
The weighted mean difference of improvement of LVEF
etween the treatment and control groups was 1.32% (95%
I1.52 to 4.16, p 0.36) (Fig. 1). There was considerable
eterogeneity between the trials (p  0.001 from the chi-
quare test, I2 71.4%). The sensitivity analysis showed that
mission of the study of Ince et al. (9) had a more
ronounced effect on the pooled result compared with other
tudies (WMD 0.17%, 95% CI1.82 to 2.17). Choosing to
mit this study from the analysis was associated with a
ramatic reduction of heterogeneity of the meta-analysis
p  0.14 from chi-square test, I2  34.4%). Metaregres-
ion indicated that CD34 cell count, number of study
atients, duration of study follow-up, method used to
easure LVEF, lack of double blinding, and change of LV
unction in the control group had no effect on the pooled
esult. The Begg adjusted rank correlation test showed no
vidence of significant bias (p  0.53), whereas the Egger
est was marginally significant (p  0.044).
The weighted mean difference of LVEF at the end of the
ollow-up period between the treatment and control groups
as 2.04% (95% CI 1.59 to 5.66, p  0.27) (Fig. 2).
here was considerable heterogeneity between the trials
p  0.001 from the chi-square test, I2  72.5%). The
ensitivity analysis showed that omission of the study of Ince
t al. (9) had a more pronounced effect on the pooled result
ompared with other studies (WMD 0.93%; 95% CI1.57 Ch T
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April 15, 2008:1429–37 Meta-Analysis of G-CSF in AMIo 3.44). Choosing to omit this study from the analysis was
ssociated with a dramatic reduction of heterogeneity of the
eta-analysis (p  0.19 from chi-square test, I2  28.2%).
Information about infarct size at the end of the follow-up
eriod was available for 6 trials. The standardized mean
ifference of reduction of infarct size between the treatment
nd control groups was 0.15 (95% CI 0.38 to 0.07, p 
.17). There was no evidence of heterogeneity between the
rials (p  0.58 from chi-square test, I2  0.0%).
linical outcome after G-CSF treatment. Data on an-
iographic restenosis were available in 9 trials (8–12,14–
7), whereas data on target vessel revascularization were
vailable in 7 trials (8,10–12,15–17). In this meta-analysis,
he restenosis rate as well as the rate of target vessel
evascularization did not significantly differ between the
-CSF and the control groups (Figs. 3 and 4). The overall
dverse event rate was low in all trials analyzed. Adverse
vents of all trials have been summarized in Table 4.
ltogether, 5 patients died: 3 in the G-CSF group and 2 in
he control group. In the G-CSF group, 1 patient died of
entricular fibrillation 12 days after enrollment (10), and for
patients who died, the cause of death was unclear because
n autopsy was not performed (12,14). In the control
Figure 1 The Effect of Stem Cell Mobilization by G-CSF on Cha
Compared with control conventional treatment, stem cell mobilization by G-CSF ha
shown by the weighted mean difference for change in left ventricular ejection fract
Integrated Revascularization and Stem Cell Liberation in Evolving Acute Myocardia
cyte Colony-Stimulating Factor ST-Segment Elevation Myocardial Infarction trial; MA
G-CSF and Intra-Coronary Stem Cell Infusion 1 trial; REVIVAL-2  Regenerate Vital
Cells in Myocardial Infarction trial.opulation, 1 patient progressed to cardiogenic shock and bied 2 days after PCI (11), and 1 patient died of chronic
eart failure after 13 months (13).
iscussion
he main findings of this meta-analysis suggest that stem
ell mobilization by G-CSF is safe and feasible but neither
mproves LV function nor reduces infarct size in patients
ith AMI after reperfusion.
There was a significant heterogeneity across trials regarding
reatment effect size. Limited sample size of available trials,
ifferences in the nature of randomization (double blind or
pen label), and variation in the methods used for measure-
ent of LVEF and in the timing of both reperfusion and
pplication of G-CSF therapy might have well contributed to
his heterogeneity, although our metaregression analysis could
ot discern any factor significantly associated with treatment
ffect size. However, sensitivity analysis showed that the study
y Ince et al. (9) had a more pronounced effect on the pooled
esult compared with other studies and that omitting this study
rom the analysis was associated with a dramatic reduction of
eterogeneity of the meta-analysis. The FIRSTLINE-AMI
rial, which included 50 patients in the 6-month follow-up and
0 patients in the 1-year follow-up, was a phase-1 randomized
f Left Ventricular Ejection Fraction
dditional beneficial effect on change in left ventricular function at follow-up as
tween treatment and control groups in individual trials. FIRSTLINE-AMI  Front-
tion trial; G-CSF  granulocyte colony-stimulating factor; G-CSF-STEMI  Granulo-
ell 1  Myocardial Regeneration and Angiogenesis in Myocardial Infarction with
rdium by Vigorous Activation of Bone Marrow Stem Cells trial; STEMMI  Stemnge o
d no a
ion be
l Infarc
GIC C
Myocaut open-label trial of G-CSF treatment initiated within
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Meta-Analysis of G-CSF in AMI April 15, 2008:1429–370 min after primary PCI in patients with AMI. In this
rial, the G-CSF–treated patients had a significant im-
rovement in LV function resulting in an improvement
n ejection fraction. In contrast, the control group had a
Figure 2 The Effect of G-CSF on Left Ventricular Ejection Fract
Compared with control groups, G-CSF had no beneficial effect on left ventricular fu
weighted mean difference of left ventricular ejection fraction at follow-up between
Figure 3 The Effect of Stem Cell Mobilization on Angiographic
Stem cell mobilization by G-CSF had no effect on angiographic restenosis rate as
by the odds ratios for angiographically assessed binary restenosis. Abbreviations aecrease in ejection fraction after 6-month and 12-month
ollow-up (9).
The main difference between the FIRSTLINE-AMI
rial and the rest of the studies included in the meta-analysis
t Follow-Up
at follow-up as shown by the
ent and control groups. Abbreviations as in Figure 1.
nosis
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April 15, 2008:1429–37 Meta-Analysis of G-CSF in AMIas seen in the control group. It has been shown recently
hat patients with AMI show an improvement in LV
unction and a reduction in infarct size within 6 months
fter coronary reperfusion (23). Accordingly, in the
EVIVAL-2 study (10), the STEMMI study (11), the
-CSF-STEMI study (12), the MAGIC CELL 1 study
16), and the Rigenera trial (15), as well as in the trials by
algimigli et al. (8), Ellis et al. (13), and Takano et al. (14),
atients in the control group showed a comparable improve-
ent in cardiac function compared with the G-CSF–
reated groups. However, the hitherto largest trial support-
ng a beneficial effect of G-CSF after AMI, the
IRSTLINE-AMI trial, showed a significant improvement
n LV function in the G-CSF group compared with the
ontrol group (9). It is noteworthy that the positive effect of
he G-CSF treatment was rather attributable to an unex-
Figure 4 The Effect of G-CSF on Target Vessel Revascularizatio
The G-CSF therapy had no effect on target vessel revascularization as shown by th
afety Characteristics of the Trials
Table 4 Safety Characteristics of the Trials
Trial
Binary Restenosis (%) T
G-CSF Control G-CSF
Valgimigli et al. (8) 0 10 0
FIRSTLINE-AMI (9) 16 20 —
REVIVAL-2 (10) 35 31 29
STEMMI (11) 10 13 10
G-CSF-STEMI (12) 21 29 21
Ellis et al. (13) — — —
Takano et al. (14) 25 26 —
Rigenera (15) 21 26 21
MAGIC Cell 1 (16) 50 30 50
Suarez de Lezo et al. (17) 0 0 0I  myocardial infarction; TVR  target vessel revascularization; other abbreviations as in Table 1.ected worsening of the LV function in the control group
uring follow-up compared with the G-CSF group (9).
The negative finding of our meta-analysis regarding the
ffect of G-CSF treatment on ventricular recovery after
MI could be explained by several factors. Mobilized stem
ells might not have homed to the infarcted myocardium
ecause of an unfavorable milieu at the time of stem cell
obilization. In patients with AMI, CD34 stem cell
obilization occurs naturally, peaking after 1 week (24,25).
oreover, the plasma level of the stem cell homing factor
DF-1 is up-regulated significantly from day 3 to day 28
fter AMI (26,27), indicating that the milieu of the injured
yocardium favors stem cell recruitment at this stage after
MI (26). Therefore, timing of cell therapy after reperfu-
ion may well affect treatment efficacy because the myocar-
ial milieu is likely to be more receptive at certain time
ratios for target vessel revascularization. Abbreviations as in Figure 1.
)
Death and Recurrent MI
(No. of Patients)
Death
(No. of Patients)
Control G-CSF Control G-CSF Control
10 0 1 0 0
— — — — —
31 1 1 1 0
10 0 1 0 1
29 2 2 1 0
— 1 1 0 1
— 1 0 1 0
26 0 0 0 0
30 0 0 0 0
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Meta-Analysis of G-CSF in AMI April 15, 2008:1429–37oints. Although we did not see an effect of the timing of
-CSF treatment on LV recovery in our multivariate analysis,
e cannot rule out that the milieu of the infarcted myocardium
id not allow significant recruitment of stem cells at the time
oint of stem cell mobilization in the trials analyzed.
The functional activity of G-CSF–mobilized stem cells
ight have been compromised because of release of immature
tem cells with limited capacity of homing to ischemic myo-
ardium due to cleavage of the functional active CXCR4
urface receptor on G-CSF mobilized stem cells (28–30).
tudy limitations. We cannot rule out that G-CSF itself
oes have a negative impact on cardiac regeneration after
MI, although treatment with G-CSF has inhibited apo-
tosis and improved survival of cardiomyocytes at a higher
ose in mice after AMI (31). On the contrary, experimental
tudies in mice and early-phase clinical trials in patients
ith coronary artery disease suggest that G-CSF may
romote atherosclerosis with the potential of adverse out-
omes in these patients (32,33). However, the overall rate of
ajor adverse cardiac events was very low in our meta-
nalysis and did not differ among patients treated with
-CSF and control. Therefore, our data are not in support
f a harmful effect of G-CSF in patients with AMI.
In the trials included, CSF effectively mobilized CD34
one marrow-derived stem cells into the circulation in a
ose-dependent manner (Table 4). However, these CD34
ells do not completely fulfill the criteria of pluripotent stem
ells with the potential to differentiate into all 3 germ layers.
n fact, these bone marrow-derived CD34 cells rather
orrespond to multipotent hematopoietic and endothelial
rogenitor cells (1,28). Therefore, the CD34 cell count in
he peripheral blood may not reliably reflect the number of
vailable multipotent cells. This may explain the lack of
mpact of CD34 cell count on the treatment effect in our
etaregression analysis.
onclusions
his meta-analysis shows that G-CSF therapy to mobilize
one marrow–derived stem cells was feasible and safe, but
n a cumulative basis it failed to improve LV recovery in
atients with AMI after reperfusion.
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